JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Clinical trial NCT02706405 · TERMINATED

Trial details

NCT number: NCT02706405
Sponsor: Fred Hutchinson Cancer Center
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Recurrent Diffuse Large B-Cell Lymphoma Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma

Start date: 2016-11-15
Primary completion: 2021-05-28
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.